A phase 3 study of ravulizumab to protect patients with chronic kidney disease from cardiac surgery-associated acute kidney injury and major adverse kidney events (ARTEMIS). - Ostermann, Marlies; Corteville, David C.; Doi, Kent; Koyner, Jay L.; Lamy, Andre; Li, Gerry; Solinsky, Christine M.; Winterberg, Pamela D.; Smith, William T.; Mehta, Ravindra L.; Murray, Patrick T.; Shaw, Andrew D.; et al. (Trials, 2025)